Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

40.83
+2.476.44%
Post-market: 40.830.00000.00%19:59 EST
Volume:1.38M
Turnover:55.82M
Market Cap:4.29B
PE:46.75
High:40.85
Open:39.01
Low:38.68
Close:38.36
52wk High:117.33
52wk Low:32.99
Shares:105.19M
Float Shares:86.88M
Volume Ratio:0.61
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8735
EPS(LYR):1.23
ROE:16.70%
ROA:5.10%
PB:6.80
PE(LYR):33.20

Loading ...

Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares

Reuters
·
Feb 06

Corcept falls as FDA reveals it warned of CRL rejection for relacorilant

TIPRANKS
·
Jan 31

Corcept Therapeutics Shares Down 16% After FDA Rejection Letter Reveals Repeated Warnings

THOMSON REUTERS
·
Jan 30

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology

Reuters
·
Jan 30

BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings

Reuters
·
Jan 30

Top Growth Companies With High Insider Ownership In January 2026

Simply Wall St.
·
Jan 26

Corcept Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jan 23

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Corcept Therapeutics (CORT), Intuitive Surgical (ISRG) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jan 23

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 23

Corcept Therapeutics (CORT.US) Announces Positive Key Phase 3 Cancer Drug Results, Potential Launch Next Year

Stock News
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel

Reuters
·
Jan 23

Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright

TIPRANKS
·
Jan 23

Corcept Therapeutics rises 17.7%

TIPRANKS
·
Jan 22

BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital

Reuters
·
Jan 22

Corcept Therapeutics Phase 3 ROSELLA Trial Achieves Survival Benefit

TIPRANKS
·
Jan 22

BUZZ-Corcept rises after ovarian cancer drug cuts risk of death in late-stage trial

Reuters
·
Jan 22

Corcept Therapeutics Shares up 34.82% Premarket After Experimental Ovarian Cancer Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Jan 22

Corcept Therapeutics reports ROSELLA trial meets primary endpoint

TIPRANKS
·
Jan 22

Corcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer

Reuters
·
Jan 22

Corcept Therapeutics Inc - Phase 3 Rosella Trial Meets Overall Survival Endpoint

THOMSON REUTERS
·
Jan 22